Opus Genetics, Inc. stock rating and score history
All changes in ratings, performance and outlook tracked over time.
Opus Genetics, Inc. stock price, chart patterns and momentum
Recent price movements, trend behaviour and momentum signals based on real-time market data.
What does Opus Genetics, Inc. do? Business model and key facts
Get the full picture of Opus Genetics, Inc.: what it builds, where it operates, and how it makes money.
Sector: Healthcare
Industry: Biotechnology
Employees (FY): 28
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis, and APX3330, a small-molecule inhibitor in its retinal pipeline that has completed Phase II trials for diabetic retinopathy. Originally founded in 2018 as Ocuphire Pharma, Inc., the company is headquartered in Farmington Hills, Michigan.
Stocks related to Opus Genetics, Inc.
Selected based on industry alignment and relative market positioning.
Events and news impacting Opus Genetics, Inc. stock
Earnings, coporate decisions and industry developments that can affect the share price.
Opus Genetics, Inc. fundamentals and technical analysis
Financial fundamentals and technicals signals combined to access stability, momentum and market direction.
